Clinical Trials in Detroit

Showing 4521-4540 of 19,719 trials

HPC Offered for PRESERVE Expansion

NCT07145411

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

Bone Marrow Transplant (BMT)

Ossium Health, Inc.10 participantsStarted Jun 2024

Birmingham, Alabama, United States • Detroit, Michigan, United States • Columbus, Ohio, United States +1 more locations

TERMINATEDPhase 2< 1 mile

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

NCT03646123

This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur. A side effect is anything the drug does besides treating cancer. This study will have three parts (Parts A, B, and C). The drugs used in Part A are a combination of targeted anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses). Part A will look at whether the A+AVD drug combination reduces the number of participants who experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white blood cell count and a fever, which can be life threatening. Parts B and C will use drug combination of brentuximab vedotin, plus nivolumab, doxorubicin, and dacarbazine. These four drugs are called "AN+AD." Parts B and C will study how well the drugs work to treat cHL and what side effects they cause.

Hodgkin Lymphoma

Seagen Inc.255 participantsStarted Jan 2019

Fountain Valley, California, United States • Aurora, Colorado, United States • Colorado Springs, Colorado, United States +73 more locations

HPC Offered for PRESERVE Expansion

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Find Trials by Condition in Detroit

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Optimizing Dimensions of Reinforcement

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Resiliency in U.S. Air Force Personnel

Improving Mobility After Revascularization in Peripheral Artery Disease

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Symptom Management Implementation of Patient Reported Outcomes in Oncology

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Multicenter Study to Evaluate the Clinical Outcome of PrimeTaper EV Implant in Single Tooth Restorations

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis